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Abstract 
Background: The goals of this study are evaluation the effect of intravenous (IV) granisetron on the duration 
of sensory and motor block produced by intrathecal hyperbaric bupivacaine and also post-operative nausea and 
vomiting in patients undergoing outpatient cystoscopy. 
Methods: 62 patients, undergoing cystoscopy received either 3 mg IV granisetron or placebo 15 minutes 
before the spinal block. Sensory and motor block were assessed after the intrathecal injection of bupivacaine 
every 2 minutes until the maximum block was achieved and thereafter every 15 minutes until recovery from 
the sensory and motor block. 
Results: Demographic data were not statistically different in the study groups. Duration of sensory and motor 
block were also not statistically different between the study groups (P = 0.060 and P = 0.070 respectively). No 
patient in either group had vomiting. Seven patients in saline and zero patient in granisetron group had nausea 
that was statistically significant (P = 0.040). Time to discharge after surgery was 243 ± 21 and 239 ± 24 
minutes in granisetron and control group respectively (P = 0.150). 
Conclusions: Systemic granisetron had no effect on the duration of sensory and motor block produced by 
spinal anesthesia with hyperbaric bupivacaine. 
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Introduction 
Several factors can influence the height and intensity of 
spinal block including the injected drug, technical 
aspects, level of injection, needle type, patient position, 
and patient characteristics, such as age, height, weight, 
pregnancy, and spinal anatomy (1). 
The 5-hydroxytryptamine Type 3 (5-HT3) 
antagonists are a class of drugs frequently used to 
prevent and treat nausea and vomiting. It has been 
shown that a 5-HT3 receptor exists in the spinal nerves 
and affects pain control in animals. The 5-HT3 binding 
sites are abundant at the spinal level (2). These 
receptors are located in the superficial laminae and 
substantia gelatinosa of the spinal cord (3). Although 
the spinal serotonergic mechanisms in pain modulation 
are complex, several studies have confirmed the role of 
5-HT3 receptors in antinociception. In humans, the
cerebrospinal fluid serotonin levels increased three-fold
after spinal bupivacaine administration. Also,
ondansetron antagonized the sensory blockade of
spinal lidocaine (4-6).
In a study by Fassoulaki et al. systemic 
administration of ondansetron, a selective 5-HT3 
antagonist, enhanced regression time of sensory block 
produced by intrathecal injection of lidocaine (7). 
However, in a study by Paraskeva et al. on 50 male 
patients undergoing transurethral surgery received 
either 8 mg oral ondansetron the evening before 
surgery plus intravenous (IV) 8 mg ondansetron 15 
minutes before subarachnoid anesthesia or placebo; it 
had no effect on the subarachnoid sensory or motor 
block produced by ropivacaine (8). 
Cystoscopy is usually an outpatient surgery, and 
patients should ambulate as early as possible; they 
should not have any motor or sensory block and also 
nausea and vomiting during discharge. So we conducted 
a study to evaluate the effect of systemic granisetron, a 
selective 5-HT3 antagonists, on the duration of sensory 
and motor block after spinal anesthesia with hyperbaric 
bupivacaine in this group of patients. 
The hypothesis of this study was that granisetron 
can enhance the regression time of sensory and motor 
block in patients who undergoing spinal anesthesia 
 with bupivacaine for outpatient cystoscopy. 
The primary aim of our study is to evaluate the 
effect of granisetron on the duration of sensory or 
motor block in spinal anesthesia with bupivacaine for 
cystoscopy that is evaluated by measuring sensory 
level regression time. The secondary aim is to evaluate 
the efficacy of granisetron on reducing nausea and 
vomiting in this group of patients. 
Materials and Methods 
This randomized double-blinded controlled trial was 
performed in Shariati Hospital of Tehran University of 
Medical Sciences since March to September of 2013. 
The study protocol conformed to the ethical guidelines 
of the 1989 Declaration of Helsinki and ethical 
approval was provided by the Ethical Committee of 
Tehran University of Medical Sciences, Tehran, Iran. 
62 patients with American Society of 
Anesthesiologists (ASA) Class I to III, aged 50-75 
years who were scheduled for diagnostic or therapeutic 
cystoscopy conducted as outpatient surgery under 
spinal anesthesia, were included and written informed 
consent was obtained separately before surgery. 
Patients with contraindications to spinal anesthesia, 
difficulty in communicating, chronic pain, neurological 
diseases, and those receiving opioids, α2 agonists and 
drugs that act on serotonin receptors or affect the level 
of serotonin were excluded. Patients were randomly 
allocated into two groups, granisetron (n = 31) or 
control saline group (n = 31). Randomization was done 
by means of computer-generated codes. All members 
of the surgical team, nursing staff, patients and the 
anesthetist were unaware of the allocation. Study drugs 
were prepared, according to the randomization code, by 
an anesthesia staff who was not involved in the study 
and envelopes containing the information of the 
randomization were sealed and kept in the patient’s 
folder until the end of the study period. Then prepared 
drugs with the same volume and shape were given to 
the anesthesiologist who was blinded to the allocation. 
On arrival to the operating room, standard 
monitoring was applied to all patients including pulse 
oximeter, electrocardiogram, non-invasive arterial blood 
pressure. An 18-gauge IV catheter was placed on the 
dorsum of the non-dominant hand of the patients, and 5 
ml/kg lactate Ringer’s solution was infused before spinal 
anesthesia. Patients received 3 mg granisetron (Kytril, 
Roche, 1 mg/ml) or the same volume of 0.9% normal 
saline solution IV, according to the allocation 15 
minutes before performing spinal anesthesia. 
All patients received no premedication and were 
blocked in the lateral position in which a 25 gauge 
Quincke needle was inserted by midline approach into 
the L3-4 or L4-5 interspaces and after ensuring the 
correct position of the needle, 12 mg of hypertonic 0.5% 
bupivacaine was injected. Patients were immediately 
placed in the supine position after the block. 
In the operating room and in the recovery room, an 
anesthesiologist who was unaware of the patient’s 
group assignment recorded the following variables: 
cephalad sensory level by loss of pinprick sensation 
bilaterally at the midclavicular line using a short-
beveled 25-gauge needle, every 2 minutes until the 
sensory block remained at the same level at two 
consecutive times and was recorded as maximal 
sensory block. 
Motor block was assessed every 2 minutes until 
maximal motor blockade using the modified Bromage 
scale, and scored as: 0 = no motor block, 1 = being 
unable to move the hip, 2 = being unable to move the 
knee, and 3 = being unable to move the ankle (8). 
Sensory and motor block were then assessed every 
15 minutes after the subarachnoid injection for 3 hours 
or until recovery from the motor block or regression of 
sensory block by two dermatomes. Patient’s age, sex, 
weight, height, ASA class, duration of surgery and also 
post-operative nausea and vomiting were all recorded 
and compared between the study groups. 
Until completion of measurements, no sedatives, 
analgesics, or other adjuvants were given 
perioperatively except for the drugs determined by the 
study protocol. Patients requiring sedatives or 
analgesics before or during the measurement of sensory 
or motor block for any reason were excluded. 
We included 31 patients in each group to detect a 
10 minutes difference in two segment regression time 
of sensory block between the study groups with 
standard deviation = 1.2, assuming a power of 90% and 
a significance level 0.05. If consecutive patients do not 
fulfill the inclusion criteria or were excluded, they are 
substituted by another one until sample size 
completion. Statistical analysis was performed using 
SPSS package (version 19, SPSS, Chicago, IL). 
Normality of distribution of data was tested by the 
Kolmogorov–Simirnov test. Data were analyzed with 
independent sample t-test, chi-square and repeated 
measured ANOVA when appropriate.  
Results 
In total, of 74 patients scheduled consecutively for 
cystoscopy, 10 were excluded due to fulfilling the 
exclusion criteria and two others for spinal block 
failure. Finally, 62 patients were allocated for statistical 
analysis (Figure 1). 
Demographic data were not statistically different in 
the study groups. None of the patients was in ASA 
Class I (Table 1). 
There was no statistical difference in the maximum 
level of sensory and motor block and their regression 
time between the study groups (Table 2). 
Time to discharge after completion of surgery was 
203 ± 24 minutes in granisetron group and 205 ± 21 
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minutes in control group (P = 0.150). No patient in 
either group had vomiting (P = 0.060). Seven patients 
in saline group and no patient in granisetron group had 
 
nausea (P = 0.040). 
No patient required IV rescue medication for pain, 
sedation or nausea. 
 
 
 
 
Figure 1. Consort flow diagram 
Table 1. Comparing demographic data and surgery time between the study groups 
Variable Granisetrone group (n = 31) Saline group (n = 31) P-value
Age (year) 59.0 ± 9.3 57.5 ± 12.1 0.500 
Sex (male/female) 20/11 18/13 0.200 
Weight (kg) 73.6 ± 8.1 71.4 ± 9.5 0.300 
Height (cm) 169.1 ± 7.6 169.1 ± 6.4 0.900 
ASA Class II/III (n) 29/2 28/3 0.300 
Duration of surgery (minutes) 63.9 ± 11.7 60.8 ± 8.1 0.200 
Data are presented as mean ± SD, number of patients (n), P < 0.050. SD: Standard deviation 
Table 2. Comparing time course of sensory and motor block between the study groups 
Variable Granisetrone group (n = 31) Saline group (n = 31) P-value 
Time to maximum sensory block (minutes) 12.4 ± 2.1 12.5 ± 1.9 0.120 
Time to maximum motor block (minutes) 16.6 ± 2.0 16.1 ± 1.9 0.230 
Time to regression of sensory level by two dermatomes 68.3 ± 8.9 68.4 ± 7.3 0.240 
Time to motor recovery by one level (minutes) 109.9 ± 14.4 112.9 ± 14.5 0.310 
Time to complete motor recovery (minutes) 161.7 ± 32.4 164.3 ± 37.1 0.520 
Maximum level of sensory block (dermatome) T10-T12 T10-T12 0.510 
Data are presented as mean ± SD, P < 0.050. SD: Standard deviation 
Assessed for eligibility (n = 74) 
Excluded (n = 12) 
• Not meeting inciusion criteria (n = 10)
• Declined to participate (n = 0)
Randomized (n = 64) 
Allocated to intervention (n = 32) 
• Received allocated intervention (n = 32)
• Did not receive allocated intervention (n = 0)
Lost to follow-up (spinal block failure) (n = 1) Lost to follow-up (spinal block failure) (n = 1) 
Analysed (n = 31) 
• Excluded from analysis (n = 0)
Analysed (n = 31) 
• Excluded from analysis (n = 0)
Allocated to intervention (n = 32) 
• Received allocated intervention (n = 32)
• Did not receive allocated intervention (n = 0)
Allocation 
Follow-Up 
Analysis 
Enrollment 
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 Discussion 
This study showed that IV granisetron had no effect on 
the maximum level and regression time of sensory and 
motor block produced by spinal anesthesia with 
hyperbaric bupivacaine. 
Our results disagree with those of Fassoulaki et al., 
who reported that systemic ondansetron, caused a 
faster regression of the sensory block after spinal 
lidocaine (7). 
However, our results correlated with those of 
Paraskeva et al. in which 50 male patients undergoing 
transurethral surgery received either 8 mg oral 
ondansetron the evening before surgery plus IV 8 mg 
ondansetron 15 minutes before subarachnoid anesthesia 
or placebo. They found that ondansetron had no effect 
on the subarachnoid sensory or motor block produced 
by ropivacaine (8). 
In a study by Mowafi et al., 40 unpre-medicated 
patients scheduled for elective knee arthroscopy under 
spinal anesthesia were randomly allocated to receive 
either IV granisetron 1 mg or saline on arrival to the 
operating room. They found that IV granisetron 
facilitated a faster recovery of the sensory block but not 
motor block after bupivacaine subarachnoid anesthesia 
which partially correlated with our study (9). 
Granisetron, in contrast to ondansetron, which acts 
on mixed receptors, strongly and selectively binds to 
the 5-HT3 receptors with minimal or no affinity for 
other 5-HT receptors, or dopaminergic, adrenergic, 
histaminic, and opioid receptors (10). 
The role of 5-HT3 receptors in pain modulation is 
conflicting, as they could mediate excitatory and 
inhibitory effects, depending on variables such as the 
concentration of 5-HT or the state 
(sensitized/desensitized) of the spinal cord (11). 
IV granisetron was also effective in preventing 
post-operative nausea in our study which correlated 
with previous studies (12,13). 
In a study by Samra et al. on 60 patients undergoing 
transurethral resection of bladder tumors, patients 
received 4 mg ondansetron or saline 15 minutes prior 
to the administration of subarachnoid block. They 
found that IV ondansetron does not affect the intensity 
or duration of sensory and motor block after spinal 
anesthesia with hyperbaric bupivacaine. They results 
were similar to ours however their drug, patients and 
surgeries were different (14). 
In another study by Rashad and Farmawy on 60 
patients undergoing elective cesarean section under 
spinal anesthesia by intrathecal bupivacaine, they 
randomly divided patients into three groups. Group O 
received IV 4 mg ondansetron 5 minutes before spinal 
anesthesia, Group G given IV 1 mg granisetron by the 
same route and Group S given 10 ml normal saline. 
They concluded that in parturient females undergoing 
elective cesarean section, IV 4 mg ondansetron before 
subarachnoid block significantly decreased both the 
hypotension and the doses of vasopressor used, while 
IV 1 mg granisetron prior to subarachnoid block 
induced faster sensory recovery compared to both the 
ondansetron and saline groups, with no significant 
differences between the latter two groups. Their finding 
was similar to ours in regard to enhanced sensory 
recovery with granisetron however we used 3 mg 
granisetron and we also did not compare hemodynamic 
responses between the study groups. They also found a 
significant decrease in the incidence of nausea in 
Groups O and G than Group S (P = 0.008) that was 
correlated with our study (15). 
In this regard, the difference of our study to 
mentioned studies may be explained by different doses 
of 5-HT3 receptors antagonists and discrepancies 
between the type, baricity and duration of the local 
anesthetics used and the different time intervals 
between block assessments. The dose of hyperbaric 
bupivacaine that was selected in our study was also not 
the best for outpatient surgery. 
Conclusion 
IV administration of 3 mg granisetron before 
intrathecal bupivacaine had no effect on recovery of 
sensory and motor block for cystoscopy as outpatient 
surgery. However, patients in granisetron had less 
nausea compared to control group. 
Further study are recommended with different 
doses of granisetron and bupivacaine on regression 
time of the spinal block in outpatient surgeries in order 
to reduce hospital staying time and also post-operative 
nausea and vomiting with only one drug. 
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